GROWTH OPPORTUNITIES IN STEM CELL THERAPY, NUCLEOTIDE DRUGS, AND THERAPEUTICS FOR CANCER AND INFECTIOUS DISEASES

GROWTH OPPORTUNITIES IN STEM CELL THERAPY, NUCLEOTIDE DRUGS, AND THERAPEUTICS FOR CANCER AND INFECTIOUS DISEASES

RELEASE DATE
18-Jun-2021
REGION
Global
Research Code: D759-00-21-00-00
SKU: HC03421-GL-TA_25513

$950.00

Special Price $855.00 save 10 %

In stock
SKU
HC03421-GL-TA_25513

$950.00

$855.00 save 10 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers innovations focused on stem cell therapy -- both allogeneic and autologous. A number of emerging technologies have been discussed for a variety of therapeutic indications including cancer, autoimmune diseases, and neurological disorders. Further, innovations on nucleic acid drugs and novel drug delivery systems have also been covered. Few innovations highlight developments in oral pox drugs, senotherapeutics, and artificial lactoferrin

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Hematopoeitic stem cells (HSC), engineered cell therapy, engineered RBC (red blood cell), immunotherapy, immune oncology, autologous cell therapy, allogeneic cell therapy, Polycythemia vera, synthetic hormone, photodynamic therapy, synthetic lactoferrin, engineered bone void filler, antisense oligonucleotides, nucleic acid therapy, centronuclear myopathy, lipid nanoparticle, drug delivery, spatial omics, pulmonary hypertension, senotherapeutics, stem cell mobilization, organ transplants, graft vs host , bone transplants, MSC (mesenchymal stem cell)

Table of Contents

INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS

  • PHOTODYNAMIC THERAPY FOR CUTANEOUS METASTATIC BREAST CANCER
  • REM-001 THERAPY FOR CMBC
  • KINTARA THERAPEUTICS – INVESTOR DASHBOARD
  • NEXT GENERATION THERAPY FOR STEM CELL MOBILIZATION
  • THERAPY FOR SOLID ORGAN TRANSPLANTS
  • TALARIS THERAPEUTICS – INVESTOR DASHBOARD
  • STEM CELL MOBILIZATION AND COLLECTION
  • MGTA-145 FOR STEM CELL TRANSPLANTS
  • MAGENTA THERAPEUTICS – INVESTOR DASHBOARD
  • GENETICALLY ENGINEERED RED BLOOD CELL THERAPEUTIC PLATFORM
  • RTX-240 THERAPY FOR CANCER TREATMENT
  • RUBIUS THERAPEUTICS – INVESTOR DASHBOARD
  • NK-CELL THERAPY FOR CANCER TREATMENT
  • POTENT IMMUNOTHERAPY FOR CANCER TREATMENT
  • KIADIS PHARMA N.V. – INVESTOR DASHBOARD
  • THERAPEUTIC STEM CELL TECHNOLOGY
  • TREATMENT FOR RARE DISEASES
  • KANGSTEM BIOTECH – INVESTOR DASHBOARD
  • AUTOLOGOUS CELLULAR THERAPY FOR NEURODEGENERATIVE DISEASES
  • NUROWN MSC-NTF TECHNOLOGY
  • BRAINSTORM CELL THERAPEUTICS – INVESTOR DASHBOARD
  • CELL ENGINEERING PLATFORM FOR UNMET MEDICAL NEEDS
  • TRANSFORMATIVE CELL THERAPY FOR MULTIPLE DISEASE AREAS
  • SANA BIOTECHNOLOGY – INVESTOR DASHBOARD
  • ALLOGENEIC CELLULAR THERAPY FOR BONE DISORDERS
  • BONE THERAPEUTICS IS OFFERING an OFF-THE-SHELF PRODUCT FOR BONE DISORDERS
  • BONE THERAPEUTICS – INVESTOR DASHBOARD
  • DEVELOPING SPATIAL OMICS 
  • DEVELOPING CELL-BASED LACTOFERRIN
  • CALCIUM-BASED BONE VOID FILLERS
  • INTRAVENOUS THERAPY FOR TREATING PULMONARY HYPERTENSION ASSOCIATED WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
  • ORAL RED BLOOD CELL PYRUVATE KINASE-R THERAPY FOR TREATING SICKLE CELL DISEASE
  • SENOTHERAPEUTICS TO REVERSE AGEING
  • NEXT-GENERATION NUCLEIC ACID-BASED CANCER THERAPY USING NOVEL DELIVERY SYSTEM
  • CENTRONUCLEAR MYOPATHIES THERAPY USING ANTISENSE OLIGONUCLEOTIDE
  • ORAL SMALLPOX MEDICATION FOR ADULT AND PEDIATRIC PATIENTS
  • SYNTHETIC HORMONE MIMETIC FOR THE TREATMENT OF POLYCYTHEMIA VERA

KEY CONTACTS

  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • LEGAL DISCLAIMER
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers innovations focused on stem cell therapy -- both allogeneic and autologous. A number of emerging technologies have been discussed for a variety of therapeutic indications including cancer, autoimmune diseases, and neurological disorders. Further, innovations on nucleic acid drugs and novel drug delivery systems have also been covered. Few innovations highlight developments in oral pox drugs, senotherapeutics, and artificial lactoferrin The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Hematopoeitic stem cells (HSC), engineered cell therapy, engineered RBC (red blood cell), immunotherapy, immune oncology, autologous cell therapy, allogeneic cell therapy, Polycythemia vera, synthetic hormone, photodynamic therapy, synthetic lactoferrin, engineered bone void filler, antisense oligonucleotides, nucleic acid therapy, centronuclear myopathy, lipid nanoparticle, drug delivery, spatial omics, pulmonary hypertension, senotherapeutics, stem cell mobilization, organ transplants, graft vs host , bone transplants, MSC (mesenchymal stem cell)
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-21-00-00
Is Prebook No
Ti Codes D759